Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR444881 Alone and in Combination in Advanced Solid Tumors
NCT04717375Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Apr 2021
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of zamristobart in solid tumor (5 arms), sponsored by Sanofi. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events, Number of Participants With Dose Limiting Toxicities and 1 more. Started Apr 2021; status: terminated.
02
Drugs
zamristobart
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04717375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04717375.